Economics & Development

Ratings of the Innovate in India for Inclusiveness for India were as follows: outcome was satisfactory, Bank performance was satisfactory, and M&E quality was substantial. Lessons and recommendations include that structured collaboration between industry, academia, and government, organized through formal milestone based consortia, is essential to accelerate translation of research into market ready health products; these models should be institutionalized through consortia based funding, embedded technology transfer offices (TTOs), and a capable public intermediary to reduce coordination failures and early stage risk. The institutional capacity of the implementing agency, including its ability to mobilize multidisciplinary support spanning science, clinical development, intellectual property, regulatory navigation, and program management, is a primary determinant of effectiveness and should be continually strengthened. Replication requires enabling conditions such as a credible institutional anchor, supportive regulatory and clinical trial capacity, and early planning for larger ticket late stage financing so that promising candidates can transition to follow on public or private capital without falling into a commercialization gap. Early market sounding should be used to calibrate grant sizes to actual costs and avoid systematic under application. Grants must be paired with expert guidance via scientific advisory groups (SAGs), a technical advisory group (TAG), and structured engagement with regulators to ensure rigor and efficient sequencing of development steps. Investments in shared innovation infrastructure should be designed as adaptable public goods to generate spillovers and bolster crisis response capacity. Sustainability of facilities and networks requires early revenue models, clear governance, and private sector participation. Procurement and fiduciary arrangements should be tailored for time sensitive science, with early planning for specialized purchases, streamlined approvals, stronger fiduciary staffing, and contingencies for government system transitions. For long gestation, portfolio based research and development, programmatic financing with phased gateways should be considered to align funding with iterative innovation cycles and reduce reliance on repeated extensions.